A GLP-1 analogue studied for metabolic regulation in controlled human trials.
In simple words
Semaglutide is a peptide modelled on GLP-1, a gut hormone involved in metabolic signalling. Controlled human studies examine body-weight and metabolic responses in specific populations.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
1,961 adults with overweight or obesity, without diabetes.
Semaglutide plus lifestyle intervention produced greater weight reduction than placebo plus lifestyle intervention over 68 weeks.
Nausea and diarrhoea were common. More participants stopped semaglutide because of gastrointestinal events. The tested formulation and trial setting matter.
PMID 33567185. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
Evidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Semaglutide
What is Semaglutide?
Semaglutide is a peptide modelled on GLP-1, a gut hormone involved in metabolic signalling. Controlled human studies examine body-weight and metabolic responses in specific populations.
What types of research are cited for Semaglutide?
The Semaglutide profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Semaglutide: STEP 1 (2021): Human — randomized controlled trial
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Semaglutide studies not establish?
Semaglutide: STEP 1 (2021): Nausea and diarrhoea were common. More participants stopped semaglutide because of gastrointestinal events. The tested formulation and trial setting matter.
These studies do not establish the identity, purity, safety or effects of the MXC Semaglutide vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.